BACKGROUND: anatomic site is a predictive factor in subtypes of cutaneous and mucosal melanoma.
a norectal mucosal melanoma (aRmm), a subtype of mucosal melanoma, remains a lethal disease with a dismal prognosis. five-year overall survival is estimated at 20% to 22% with a disease-free survival of 16% to 17%. [1] [2] [3] [4] [5] [6] [7] [8] anorectal mucosal melanoma accounts for between 1% and 2% of lower Gi malignant tumors and 0.4% and 1.6% of all melanomas. 2, 3, 9 although the reasons remain unclear, the incidence of aRmm is thought to be increasing. 1, 4, 10 after mucosal melanoma of the head and neck and female genital tract, melanoma of the anorectum is the third most common mucosal site of involvement. 1 Diagnosis is often delayed because these tumors are amelanotic in 20% to 25% of cases and are often confused with benign diseases such as hemorrhoids. 3, 4, 6, 11, 12 sixtyfive percent of anorectal melanomas are located within the anal canal or anal verge; however, in 35% of cases, disease is also found in the distal rectum. 5, 10 Yap and neery 9 categorized anorectal melanoma by location, defining anal as lesions situated below the dentate line, rectal as masses located above the dentate line, and anorectal if the tumor was located around the dentate line.
in this disease, recurrence is most often distant and fatal. Perineural invasion in the primary tumor has been suggested to be a predictor of poor outcome. 7 unlike in cutaneous melanoma, lymph node status has not been linked to recurrence or survival outcome in aRmm. 6, 7 Despite the use of multiple treatment modalities, including surgery, radiotherapy, and systemic therapy, prognosis and overall survival remain bleak for aRmm. in general, the stage at diagnosis is advanced, with regional and systemic metastases rates as high as 20% and 40%. [1] [2] [3] [4] [5] 10, 13 neither abdominopelvic resection (aPR) nor wide local excision (Wle) has clearly shown a survival benefit. 2, 7, 9, [12] [13] [14] although Wle may be associated with a higher rate of local recurrence, a higher morbidity is associated with aPR. multiple investigators now advocate for the use of Wle, reserving aPR only for tumors not amenable to local excision or for palliative treatment of large, obstructing lesions. 2, 7, 9, 12, 14 there may be some role for radiation as palliative therapy in locally advanced, recurrent, or metastatic disease, but this too has not impacted survival.
in both cutaneous and mucosal melanoma, the site of origin predicts prognosis. in several studies to date, it has been shown that patients with scalp or neck melanoma have a lower 5-year survival than other anatomic sites. 15, 16 analysis of the surveillance, epidemiology, and end Results database demonstrated that cutaneous melanomas arising from the scalp and neck, even when adjusted for age, sex, thickness, and ulceration, had almost 2 times the rate of melanoma-specific death (hR, 1.84; 95% Ci, 1.62-2.10) than melanomas arising from the extremity. 16 in both mucosal melanoma of the head and neck and of the female genital tract, the primary melanoma site also correlates with survival. [17] [18] [19] [20] for example, vulvar mucosal melanomas have a superior 5-year overall survival (8%-55%) in comparison with that of vaginal melanoma (5%-25%). 17, [19] [20] although rich lymphatic and vascular drainage, diagnostic difficulty, cosmetic concerns, and molecular differences have been hypothesized to play a role, the exact reason for these poorer survival outcomes by anatomic site still remains unclear.
no study to date has examined whether survival differences exist in terms of clinical behavior in aRmm by site. this study investigates the clinical relevance of the location of origin of aRmm as a prognostic factor.
METHODS
Data were obtained from a prospectively maintained database at memorial sloan-Kettering Cancer Center (msKCC). the institutional review board approved the use and analysis of these data. Patients with incomplete records (n = 1), metastases at diagnosis (n = 17), or who did not undergo primary tumor resection (n = 6) were excluded. tumors were defined as anal if they were distal to the dentate line and rectal if they were proximal to it. lesions traversing or arising from the dentate line were called anorectal. all rectal lesions (n = 32) were classified as proximal to, and not including, the dentate line. if location could not be definitively identified, pathologic results documenting type of mucosa -either columnar or squamous -were used to ascertain if the lesion was anorectal or anal in origin (table 1). in addition, lymph node basins were used to help determine anatomic site; patients with inguinal adenopathy were classified as anal, whereas those with mesenteric lymphadenopathy were classified as rectal or anorectal in origin. of our entire series, 85% of aRmm (n = 82) tumors were classified by the anatomic location criteria defined in table 1. fourteen patients (15%) were classified according to the secondary characteristics of histology (n = 9) and lymph node drainage patterns (n = 5) listed in table 1. half of these were anal (n = 7) and half were anorectal (n = 7).
Patients who underwent transanal excision or abdominoperineal resection but were referred to msKCC for later management were included in this database. these patients underwent pathologic review at msKCC. margin status was documented in all but 5 patients (4 anal and 1 anorectal). Recurrences were identified from clinical follow-up visits and radiographic studies. they were categorized as local, nodal, or systemic. local recurrences were defined as recurrences at the site of resection, nodal recurrences were defined as recurrences in the draining • Anal was defined as distal to the dentate line • Anorectal was defined as at or traversing the dentate line • Rectal was defined as proximal to the dentate line If exact anatomic location is uncertain:
• Histology:
• Anal melanoma was identified by squamous mucosa • Anorectal or rectal melanoma was identified by colonic mucosa • Lymphatic drainage:
• 
RESULTS
the prospective melanoma database identified 120 patients diagnosed with anorectal melanoma from 1994 to 2010. after exclusion by the previously described criteria, 96 patients remained, of which 41 had anal tumors, 32 had anorectal tumors, and 23 had rectal tumors.
Patient Demographics and Primary Tumor Characteristics
Clinical and pathologic data describing patients in the anal, anorectal, and rectal groups are listed in table 2. there was no difference between these 3 groups in median age and sex; all 3 anatomic sites demonstrated a female predominance. all patients diagnosed with anal melanoma in this series were white, whereas anorectal and rectal melanomas were found in black, asian, and white patients. although no staging system has been shown to reliably divide cases of aRmm into low-or high-risk groups, there is a trend toward significance of anal lesions being discovered at an earlier stage by the use of the 2010 american Joint Committee on Cancer Cutaneous melanoma staging system 21 than anorectal or rectal lesions (p = 0.056). approximately 37% of anal lesions were diagnosed as stage iiB or less versus 22% of anorectal and 26% of rectal lesions. The majority of tumors of anal, anorectal, and rectal origin were advanced in thickness at diagnosis. however, anal melanoma tumors presented at a lesser median depth in comparison with anorectal and rectal melanomas (p = 0.002). a significant percentage (37%) of anal lesions were diagnosed ≤4.00 mm, 10% of which were ≤2.00 mm, whereas only 6% of anorectal lesions and 9% of rectal tumors were found with a thickness of ≤4.00 mm, and none of these tumors had a depth of ≤2.00 mm. multifocal disease was found in 14% of anal lesions, 22% of anorectal tumors, and 17% of rectal lesions; this difference was not significant. a high percentage of anal (68%), anorectal (62.5%), and rectal (48%) lesions were ulcerated or had an unknown ulceration status, but there were no significant differences between these groups. When documented, anal lesions had a higher prevalence of lymphovascular invasion (lVi) (22%) and perineural invasion (Pni) (15%) relative to anorectal (19% lVi, 6% Pni) or rectal (13% lVi, 4% Pni) tumors. however, there was no significant difference in lVi or Pni status between primary sites. When documented on pathologic inspection, there was a mitotic index ≥1 identified in 39% of anal lesions in comparison with 19% of anorectal and 17% of rectal tumors. this difference was not statistically significant.
Surgical Management all patients underwent surgery in our series. all patients but one (98%) with anal melanoma underwent transanal excision in comparison with 78% of anorectal tumors and 70% of rectal tumors (p < 0.02) (table 3) . the abdominoperineal resection rate for anorectal melanoma was 22%, and, for rectal melanoma, the abdominoperineal resection rate was 26%. one patient with a high rectal melanoma 10 cm from the anal verge underwent a low anterior resection. margin positivity was similar between groups. anal melanoma tumors had positive margins in 29% of patients, anorectal in 22%, and rectal in 22%. upon closer analysis of margin positivity, no patients had oral or proximal margins positive alone. for anal tumors with positive margins (n = 12), 7 (58%) had deep or vertical margins positive, 2 (17%) had anal margins positive, and 2 (17%) had all margins positive. specific margins were not stated for 1 (8%) patient. for patients who had anorectal tumors with positive margins (n = 7), 1 (14%) patient was positive at the deep margins, 4 (57%) patients had all margins positive, and 2 (29%) patients' margin status was unspecified. no patients had anal or distal margins positive. lastly, of the patients who had rectal tumors with positive margins (n = 5), 2 patients (40%) had deep margins positive, 1 (20%) had anal margins positive, and 1 (20%) had all margins positive. one patient's margin location (20%) was unspecified. Because of the small number of patients in each group, there was no statistical difference in margin location between anatomic sites. in addition, because of the small sample size, it is difficult to draw definitive conclusions from these data. Deep margins were most often positive in the anal and rectal groups, whereas all margins were most often positive in the anorectal groups. many of the patients with positive margins underwent reexcision to gain local control of this disease. in agreement with previous studies, there was no difference in survival between patients who underwent curative Wle or curative aPR, in which all known tumor was removed. 2, 7, [12] [13] [14] Where Wle is unable to remove all tumor, aPR should be performed. in our patient population, when local control could not be achieved through Wle, aPR was offered.
Probably because of the accessibility of anal lesions, sentinel lymph node biopsy (slnB) was more commonly performed in patients with anal melanoma (27%) than in patients with anorectal tumors (6%) and rectal tumors (0%; p = 0.004). of patients who underwent slnB, 64% of slnBs in anal tumors and 100% of slnBs in anorectal tumors were positive for melanoma. of the 7 patients who had anal melanoma with a positive slnB, 3 (43%) underwent a completion lymph node dissection, whereas all of the patients who had anorectal melanoma underwent a completion lymph node dissection. few patients underwent adjuvant radiation; there was no difference by anatomic site. Adjuvant treatment, including different chemotherapeutic regimens and types of immunotherapy, was administered to patients at similar rates by site of origin. Adjuvant therapy did not demonstrate any survival benefit for the entire series and when broken down by cohort.
Patterns of Recurrence and Survival
median length of follow-up was 22 months for our patient series. median follow-up for each cohort was 20 months for anal tumors and 24 months for anorectal and rectal tumors. of the 12 patients lost to follow-up, 7 (17%) had anal tumors, 4 (13%) had anorectal tumors, and 1 (4%) had a rectal tumor. the distribution of recurrence by site is depicted in table 4. anal primary lesions metastasized to lymph nodes, either alone or in combination with systemic disease, initially (p = 0.016) and more often overall (p < 0.001) in comparison with anorectal or rectal melanoma lesions. those anorectal and rectal tumors that recurred regionally frequently recurred in the inguinal lymph node basin. however, eventually the disease, regardless of site of origin, becomes systemic with 75% of anal lesions, 78% of anorectal lesions, and 63% of rectal tumors eventually recurring systemically. Recurrence-free survival was not significantly different by site of origin ( fig. 1 ). the median time to recurrence was 23 months for anal, 28 months for anorectal, and 27 months for rectal tumors. median overall survival (os) was not different by site; median os for anal tumors was 22 months, for anorectal tumors it was 28 months, and for rectal tumors it was 27 months. Despite being diagnosed at an earlier depth, 5-year os was shorter for anal tumors (11%) than for anorectal (24%) and rectal tumors (18%), although this difference was not significant ( fig. 2 ).
DISCUSSION
to our knowledge, this is the first article examining the role of the anatomic site of aRmm in prognosis. Clinical differences between the primary site of disease in this series do exist. in our study, anal melanoma was more common in the white population. although it is interesting to note that racial differences exist by anatomic site, because the patient numbers are small, it is difficult to draw many conclusions from this finding. it is known that, although the absolute incidence of mucosal melanoma is greatest in whites, the proportion of aRmm in blacks, hispanics, and asians, similar to other types of mucosal melanoma, is greater than that observed in whites. 1, 17 in addition, patterns of racial distribution may be reflective of an institutional referral bias. Differences in Breslow thickness can be seen between primary tumor sites, and thinner lesions are observed in the anal melanoma group. anal melanoma tumors are also diagnosed at earlier stages. this may be because some anal lesions are identified by visual inspection of the anal verge, whereas anorectal and rectal tumors are often diagnosed only when patients are symptomatic from disease. Despite some anal tumors being thinner at the time of diagnosis, diagnosis at an earlier pathologic stage does not significantly alter survival outcomes in comparison with anorectal or rectal primary sites. Patterns of surgical management differ by primary location. Although the majority of patients with anal melanoma underwent transanal excision, in part, owing to the fact that no surgical operation has shown a survival benefit and transanal excision has a lower morbidity than aPR, patients with anorectal or rectal melanoma were more likely to undergo aPR. abdominopelvic resection is often reserved for cases not amenable to local excision or for palliation. Because aRmm can often be multifocal and amelanotic in up to 20% to 25% of cases, achieving curative resection by Wle can be challenging. 5 in addition, the radial growth phase component of a melanoma may extend beyond the visible tumor. these factors probably also contributed to our margin positivity rate. sentinel lymph node biopsy was performed in more patients with anal melanoma, perhaps because of its distal location and technical feasibility in comparison with more proximal tumors. it is noteworthy that slnB had been performed on mucosal melanoma tumors as part of a previous institutional protocol. Because lymph node status has not proven to be prognostic in anorectal melanoma, and given that no therapy has demonstrated an improvement in survival, there was no standardization of management based on the results of these biopsies.
there was no improvement in survival for those patients who received adjuvant systemic or radiation therapy in our study. Because no level 1 or 2 evidence exists to direct the physician in the management of aRmm in the adjuvant setting, the standard of care is observation. If a patient develops systemic metastases or the risk of systemic metastases is considered high, adjuvant therapy is administered or patients are enrolled in clinical trials at our institution in which they receive it.
Patterns of recurrence differed between these groups. anal melanomas more frequently recurred in the lymph nodes initially, either alone or in combination with distant disease, compared with more proximal tumors. this recurrence pattern may be a reflection of initial surgical intervention; patients with anorectal or rectal melanoma undergoing aPR have their draining lymph node basin removed in the mesorectum at the initial operation, whereas those with anal lesions, who mostly underwent transanal excision, had their nodal basin left intact. this pattern may also reflect a difference in the ability to detect lymph node metastases by anatomic location. inguinal adenopathy is more readily detected on physical examination, whereas mesorectal lymph node metastases require radiographic imaging for discovery. therefore, inguinal adenopathy may be more easily recognized and diagnosed for anal lesions, whereas mesorectal lymphadenopathy may not be apparent until cross-sectional imaging is performed to assess for systemic disease. Despite these differences in tumor thickness, surgical resection, and recurrence patterns, os is not significantly different among aRmm of distinct primary sites. these findings reinforce the need for continued research in this disease. Because of the uniformly poor prognosis of aRmm, efforts centering on combining surgical excision with systemic therapy as first-line treatment are ongoing, and effective systemic therapy is required for the successful treatment of this disease.
Recently, significant advances have been made in the field of both immunotherapy and targeted therapy in the treatment of cutaneous metastatic melanoma. ipilimumab, a new human monoclonal antibody that targets cytotoxic t-lymphocyte antigen 4, was the first agent to show improvement in os in patients with metastatic melanoma in a phase iii, randomized, control trial. 22, 23 in addition, vemurafenib, an inhibitor of mutant BRaf, has demonstrated a significant impact on both progression-free and os in a phase iii trial in patients with melanoma containing the V600e BRaf mutation. lastly, various inhibitors of Kit, such as imatinib mesylate, sunitinib, nilotinib, and dasatinib, have also demonstrated activity in a subset of patients with metastatic melanoma harboring Kit alterations. 24 it is known that certain mucosal melanomas, including aRmm, contain these BRaf and Kit mutations at varying rates according to anatomic site. 25, 26 thus, it can be hypothesized that some aRmm may represent better targets for drugs, such as ipilimumab, that function through immune system modulation, whereas those melanomas that demonstrate a specific actionable mutation may respond more optimally to targeted inhibitors, such as imatinib and vemurafenib. at present, no data are available on these new effective immune therapeutic agents and targeted drugs in the treatment of aRmm specifically. however, new trials using these agents, including ipilimumab, BRaf and Kit inhibitors, for the treatment of all mucosal melanomas, are underway.
our study has a few limitations. for the purpose of this study, we excluded patients with distant metastases who were not considered for curative resection. in doing so, our data represent outcomes for patients considered good surgical risks, most of whom were referred to our institution for surgical treatment and therefore contain a certain selection bias. Because anorectal melanoma is a rare disease, our total population is relatively small, with our anatomic subsets including a limited number of patients, increasing the possibility of type ii error. also, given that some patients were lost to follow-up, there were limitations in our ability to accurately assess dates of recurrence and, therefore, recurrence-free survival. lastly, when defining primary anatomic location, not all anal tumors could be definitively confirmed as mucosal melanomas. two anal tumors may have been located on perianal skin. however, description of these lesions as documented by physical examination was consistent with anal verge melanoma. therefore, we have chosen to include these 2 patients with anal melanomas because of the likelihood that these tumors were mucosal melanomas.
CONCLUSIONS
this study represents the only series describing the outcomes of anorectal melanoma by anatomic location of the primary lesion. lesions at or proximal to the dentate line present with more advanced disease, possibly related to a delay in diagnosis. lesions distal to the dentate line more commonly recur within lymph nodes, which may represent differences in nodal drainage. irrespective of location, long-term prognosis remains poor for all cases of aRmm; however, progress in the development of systemic therapy for this disease holds the promise for improved outcomes in the future.
